Case Study: Nitrosamine Risk Assessment and Confirmatory LC-MS/MS Testing for a Metformin Generic
The Critical Role of Nitrosamine Testing for a Metformin Generic Nitrosamine Testing for a Metformin Generic is a critical regulatory […]
Comparing Degradation Rates of PLGA, PLA, and PCL: A Formulator’s Reference Guide
Designing Controlled-Release Systems Through Aliphatic Polyester Erosion Selecting the most appropriate bioresorbable matrix for long-acting drug delivery systems or implantable
Comparing Degradation Rates of PLGA, PLA, and PCL: A Formulator’s Reference Guide Read More »
PLGA in CNS Drug Delivery: Strategies for Crossing the Blood-Brain Barrier
Introduction to PLGA CNS Drug Delivery Blood-Brain Barrier Systems PLGA CNS Drug Delivery Blood-Brain Barrier systems are advanced polymeric nanocarriers
PLGA in CNS Drug Delivery: Strategies for Crossing the Blood-Brain Barrier Read More »
FDA vs EMA Biosimilar Regulatory Pathways: Key Differences and What They Mean for Your Programme
Introduction Navigating FDA vs EMA biosimilar regulatory pathways is one of the most strategically consequential decisions a biopharmaceutical developer makes
Bioanalytical Services for Rare Disease Drug Development: Unique Challenges and CRO Selection
Introduction Within the highly specialized field of drug development, implementing advanced Bioanalytical Services for Rare Disease programs is essential for
What Is the Difference Between a Nitrosamine Impurity and a Nitrosamine Leachable?
Process vs. Material Origins Nitrosamine impurities originate from active pharmaceutical ingredient (API) synthetic pathways, degraded raw materials, or chemical interactions
What Is the Difference Between a Nitrosamine Impurity and a Nitrosamine Leachable? Read More »
Peptide Characterization CRO Deliverables Checklist: What Your Analytical Data Package Must Include
The Regulatory Imperative for a Peptide Characterization CRO Deliverables Checklist A peptide characterization CRO deliverables checklist serves as a fundamental
What is Biosimilar Development? A Step-by-Step Guide from Molecule to Market
Introduction: Biosimilar development is one of the most scientifically rigorous and regulatory-intensive processes in modern pharmaceutical science — and navigating
What is Biosimilar Development? A Step-by-Step Guide from Molecule to Market Read More »
Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA: Key Formulation Differences
Introduction to Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA The development of clinically successful long-acting parenteral formulations depends on aligning
Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA: Key Formulation Differences Read More »
Do All Drug Products Need a Nitrosamine Risk Assessment? FDA’s Risk-Based Approach Explained
Assessing the chemical safety of human drug products requires a thorough understanding of potential mutagenic and carcinogenic impurities that fall